Ara Metjian
Overview
Explore the profile of Ara Metjian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fatola A, Fatola A, Evans M, Brown J, Davis E, Johnson A, et al.
Blood Adv
. 2024 Dec;
9(2):417-424.
PMID: 39626301
Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody-mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab effect...
2.
Abou-Ismail M, Zhang C, Presson A, Chaturvedi S, Antun A, Farland A, et al.
Res Pract Thromb Haemost
. 2024 Apr;
8(3):102388.
PMID: 38651093
Background: Mortality due to immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains significant. Predicting mortality risk may potentially help individualize treatment. The French Thrombotic Microangiopathy (TMA) Reference Score has not been externally...
3.
Abou-Ismail M, Zhang C, Presson A, Chaturvedi S, Antun A, Farland A, et al.
Blood Adv
. 2023 Dec;
8(3):620-623.
PMID: 38100454
No abstract available.
4.
Tarantino M, Hardesty B, Metjian A, Ortel T, Chen J, Badejo K, et al.
Haemophilia
. 2023 Aug;
29(5):1259-1268.
PMID: 37584309
Introduction: Recombinant porcine factor VIII (rpFVIII, susoctocog alfa) is indicated for the treatment of bleeding episodes in adults with acquired haemophilia A (AHA). Aim: To provide long-term real-world safety and...
5.
6.
Scully M, Rubia J, Pavenski K, Metjian A, Knobl P, Peyvandi F, et al.
J Thromb Haemost
. 2022 Sep;
20(12):2810-2822.
PMID: 36138517
Introduction: Caplacizumab demonstrated efficacy and safety in patients with immune-mediated thrombotic thrombocytopenic purpura (iTTP) in the phase 3 HERCULES trial. However, data on long-term outcomes following caplacizumab treatment are limited....
7.
Shah H, Chen H, Pan X, Metjian A, Brodsky R, Braunstein E, et al.
Blood Adv
. 2022 Aug;
6(23):6071-6074.
PMID: 35914225
No abstract available.
8.
Chaturvedi S, Antun A, Farland A, Woods R, Metjian A, Park Y, et al.
Blood
. 2022 Jul;
140(12):1335-1344.
PMID: 35797471
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is characterized by recurring episodes of thrombotic microangiopathy, causing ischemic organ impairment. Black patients are overrepresented in iTTP cohorts in the United States, but racial...
9.
Josephson C, Goldstein S, Askenazi D, Cohn C, Spinella P, Metjian A, et al.
Transfusion
. 2021 Dec;
62(2):396-405.
PMID: 34931321
Background: This study investigated the real-world safety and tolerability of solvent/detergent-treated (S/D) plasma for pediatric patients requiring therapeutic plasma exchange (TPE). Study Design And Methods: LAS-213 was a multicenter, open-label,...
10.
Peyvandi F, Cataland S, Scully M, Coppo P, Knoebl P, Kremer Hovinga J, et al.
Blood Adv
. 2021 Apr;
5(8):2137-2141.
PMID: 33881463
The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of...